Guideline update for MASCC and ESMO in the prevention of chemotherapy-and radiotherapy-induced nausea and vomiting: Results of the Perugia consensus conference

F. Roila; J. Herrstedt; M. Aapro; R. J. Gralla; L. H. Einhorn; E. Ballatori; E. Bria; R. A. Clark-Snow; B. T. Espersen; P. Feyer; S. M. Grunberg; P. J. Hesketh; K. Jordan; M. G. Kris; E. Maranzano; A. Molassiotis; G. Morrow; I. Olver; B. L. Rapoport; C. Rittenberg; M. Saito; M. Tonato; D. Warr

doi:10.1093/annonc/mdq194

Guideline update for MASCC and ESMO in the prevention of chemotherapy-and radiotherapy-induced nausea and vomiting: Results of the Perugia consensus conference

F. Roila, J. Herrstedt, M. Aapro, R. J. Gralla, L. H. Einhorn, E. Ballatori, E. Bria, R. A. Clark-Snow, B. T. Espersen, P. Feyer, S. M. Grunberg, P. J. Hesketh, K. Jordan, M. G. Kris, E. Maranzano, A. Molassiotis, G. Morrow, I. Olver, B. L. Rapoport, C. RittenbergM. Saito, M. Tonato, D. Warr

Research output: Contribution to journal › Article › peer-review

600 Scopus citations

Original language	English (US)
Pages (from-to)	v232-v243
Journal	Annals of Oncology
Volume	21
Issue number	SUPPL. 5
DOIs	https://doi.org/10.1093/annonc/mdq194
State	Published - May 2010
Externally published	Yes

ASJC Scopus subject areas

Hematology
Oncology

Access to Document

10.1093/annonc/mdq194

Cite this

Roila, F., Herrstedt, J., Aapro, M., Gralla, R. J., Einhorn, L. H., Ballatori, E., Bria, E., Clark-Snow, R. A., Espersen, B. T., Feyer, P., Grunberg, S. M., Hesketh, P. J., Jordan, K., Kris, M. G., Maranzano, E., Molassiotis, A., Morrow, G., Olver, I., Rapoport, B. L., ... Warr, D. (2010). Guideline update for MASCC and ESMO in the prevention of chemotherapy-and radiotherapy-induced nausea and vomiting: Results of the Perugia consensus conference. Annals of Oncology, 21(SUPPL. 5), v232-v243. https://doi.org/10.1093/annonc/mdq194

Roila, F, Herrstedt, J, Aapro, M, Gralla, RJ, Einhorn, LH, Ballatori, E, Bria, E, Clark-Snow, RA, Espersen, BT, Feyer, P, Grunberg, SM, Hesketh, PJ, Jordan, K, Kris, MG, Maranzano, E, Molassiotis, A, Morrow, G, Olver, I, Rapoport, BL, Rittenberg, C, Saito, M, Tonato, M & Warr, D 2010, 'Guideline update for MASCC and ESMO in the prevention of chemotherapy-and radiotherapy-induced nausea and vomiting: Results of the Perugia consensus conference', Annals of Oncology, vol. 21, no. SUPPL. 5, pp. v232-v243. https://doi.org/10.1093/annonc/mdq194

@article{2ccd38039336453d8357a664f0092ffd,

title = "Guideline update for MASCC and ESMO in the prevention of chemotherapy-and radiotherapy-induced nausea and vomiting: Results of the Perugia consensus conference",

author = "F. Roila and J. Herrstedt and M. Aapro and Gralla, {R. J.} and Einhorn, {L. H.} and E. Ballatori and E. Bria and Clark-Snow, {R. A.} and Espersen, {B. T.} and P. Feyer and Grunberg, {S. M.} and Hesketh, {P. J.} and K. Jordan and Kris, {M. G.} and E. Maranzano and A. Molassiotis and G. Morrow and I. Olver and Rapoport, {B. L.} and C. Rittenberg and M. Saito and M. Tonato and D. Warr",

note = "Funding Information: Conflict of interest: Dr Roila has reported that he is a member of the advisory board for Helsinn SA, that in the last years he participated in researches sponsored by GSK, Merck Sharp & Dhome and Helsinn and that he has been a speaker at satellite symposia for GSK, Merck Sharp & Dhome and Helsinn; Dr Herrstedt has reported that he is a member of the speakers{\textquoteright} bureau for Merck; Dr Aapro has reported that he is a consultant for Helsinn, Merck, Novartis, Roche and Sanofi-Aventis; Dr Gralla has not reported any conflicts of interest; Dr Einhorn has reported that he holds stock in GlaxoSmithKline; Dr Ballatori has reported no conflicts of interest; Dr Bria has reported no conflicts of interest; Dr Clark-Snow has reported no conflicts of interest; Dr Espersen has reported no conflicts of interest; Dr Feyer has reported no conflicts of interest; Dr Grunberg hasreportedthat hehasservedasa consultanttoHelsinn,Merck,GlaxoSmithKline,SNBL and Prostrakan, he holds stock in Merck and has received lecture honoraria from Merck; Dr Hesketh has reported that he has received research funding from Eisai and Merck and that he serves as consultant on the advisory boards of Helsinn, Merck and GlaxoSmithKline; Dr Jordan has reported that she is a member of the speakers{\textquoteright} bureau of MSD and Helsinn; Dr Kris has reported that he serves as a consultant to Merck and GlaxoSmithKline; Dr Maranzano has reported no conflicts of interest; Dr Molassiotis has reported that he has received honoraria from Roche UK Ltd, Merck, GlaxoSmithKline, Bayer-Schering and research grants from Roche UK Ltd and Merck; Dr Morrow has reported that he is a speaker for EISAI; Dr Olver has reported no conflicts of interest; Dr Rapoport has reported that he is a member of the Merck antiemetic advisory board; Dr Rittenberg has reported no conflicts of interest; Dr Saito has reported no conflicts of interest; Dr Tonato has reported no conflicts of interest; Dr Warr has reported that he is a member of the speakers{\textquoteright} bureau and a consultant for Merck.",

year = "2010",

month = may,

doi = "10.1093/annonc/mdq194",

language = "English (US)",

volume = "21",

pages = "v232--v243",

journal = "Annals of Oncology",

issn = "0923-7534",

publisher = "Oxford University Press",

number = "SUPPL. 5",

}

TY - JOUR

T1 - Guideline update for MASCC and ESMO in the prevention of chemotherapy-and radiotherapy-induced nausea and vomiting

T2 - Results of the Perugia consensus conference

AU - Roila, F.

AU - Herrstedt, J.

AU - Aapro, M.

AU - Gralla, R. J.

AU - Einhorn, L. H.

AU - Ballatori, E.

AU - Bria, E.

AU - Clark-Snow, R. A.

AU - Espersen, B. T.

AU - Feyer, P.

AU - Grunberg, S. M.

AU - Hesketh, P. J.

AU - Jordan, K.

AU - Kris, M. G.

AU - Maranzano, E.

AU - Molassiotis, A.

AU - Morrow, G.

AU - Olver, I.

AU - Rapoport, B. L.

AU - Rittenberg, C.

AU - Saito, M.

AU - Tonato, M.

AU - Warr, D.

N1 - Funding Information: Conflict of interest: Dr Roila has reported that he is a member of the advisory board for Helsinn SA, that in the last years he participated in researches sponsored by GSK, Merck Sharp & Dhome and Helsinn and that he has been a speaker at satellite symposia for GSK, Merck Sharp & Dhome and Helsinn; Dr Herrstedt has reported that he is a member of the speakers’ bureau for Merck; Dr Aapro has reported that he is a consultant for Helsinn, Merck, Novartis, Roche and Sanofi-Aventis; Dr Gralla has not reported any conflicts of interest; Dr Einhorn has reported that he holds stock in GlaxoSmithKline; Dr Ballatori has reported no conflicts of interest; Dr Bria has reported no conflicts of interest; Dr Clark-Snow has reported no conflicts of interest; Dr Espersen has reported no conflicts of interest; Dr Feyer has reported no conflicts of interest; Dr Grunberg hasreportedthat hehasservedasa consultanttoHelsinn,Merck,GlaxoSmithKline,SNBL and Prostrakan, he holds stock in Merck and has received lecture honoraria from Merck; Dr Hesketh has reported that he has received research funding from Eisai and Merck and that he serves as consultant on the advisory boards of Helsinn, Merck and GlaxoSmithKline; Dr Jordan has reported that she is a member of the speakers’ bureau of MSD and Helsinn; Dr Kris has reported that he serves as a consultant to Merck and GlaxoSmithKline; Dr Maranzano has reported no conflicts of interest; Dr Molassiotis has reported that he has received honoraria from Roche UK Ltd, Merck, GlaxoSmithKline, Bayer-Schering and research grants from Roche UK Ltd and Merck; Dr Morrow has reported that he is a speaker for EISAI; Dr Olver has reported no conflicts of interest; Dr Rapoport has reported that he is a member of the Merck antiemetic advisory board; Dr Rittenberg has reported no conflicts of interest; Dr Saito has reported no conflicts of interest; Dr Tonato has reported no conflicts of interest; Dr Warr has reported that he is a member of the speakers’ bureau and a consultant for Merck.

PY - 2010/5

Y1 - 2010/5

UR - http://www.scopus.com/inward/record.url?scp=77954319603&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77954319603&partnerID=8YFLogxK

U2 - 10.1093/annonc/mdq194

DO - 10.1093/annonc/mdq194

M3 - Article

C2 - 20555089

AN - SCOPUS:77954319603

SN - 0923-7534

VL - 21

SP - v232-v243

JO - Annals of Oncology

JF - Annals of Oncology

IS - SUPPL. 5

ER -

Guideline update for MASCC and ESMO in the prevention of chemotherapy-and radiotherapy-induced nausea and vomiting: Results of the Perugia consensus conference

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this